LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences ...
GAITHERSBURG, MD, USA I 10, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ ...
EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...
LAUSANNE, Switzerland I 10, 2024 I AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for ...
NEW YORK, NY, USA I 05, 2024 I Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the ...
Following this Series B round, Geert-Jan Mulder, Managing Partner at Forbion, Florian Muellershausen, Managing Director at Novartis Venture Fund, and a representative of JJDC, will join Citryll’s ...
MANNHEIM, Germany I December 09, 2024 I Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to ...
Data demonstrate engineered tRNA from company's first development candidate restores protein production to clinically meaningful levels in two disease ...
The BEXMAB study is a multicenter study, taking place in Finland, UK and the U.S., evaluating the safety and efficacy of bexmarilimab, a novel anti-Clever-1 humanized antibody, with standard of care ...
BASEL, Switzerland I December 09, 2024 I Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for ...
PHILADELPHIA, PA, USA I 09, 2024 I GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) ...
In single-ascending dose study in VWD patients, a subcutaneous dose of VGA039 was associated with substantial reductions in bleeds ...